Quarterly ResultAug 13, 2026, 07:37 AM
CorMedix Q2 2026 Revenue $101.9M, Net Income $26.0M; Raises EBITDA Guidance
AI Summary
CorMedix Inc. reported strong second-quarter 2026 financial results, with consolidated revenue of $101.9 million and net income of $26.0 million. Adjusted EBITDA reached $58.7 million, and basic EPS was $0.33. The company also announced a new multi-year commercial supply agreement for DefenCath, expanding its footprint to all top 5 U.S. dialysis providers. CorMedix maintained its full-year 2026 revenue guidance while raising its adjusted EBITDA guidance to $125 million to $140 million.
Key Highlights
- Q2 2026 consolidated revenue reached $101.9 million.
- Q2 2026 net income was $26.0 million, with basic EPS of $0.33.
- Adjusted EBITDA for Q2 2026 was $58.7 million.
- Full-year 2026 adjusted EBITDA guidance raised to $125M-$140M.
- DefenCath sales contributed $66.1 million in Q2 2026.
- Melinta portfolio contributed $35.8 million in Q2 2026.
- Signed new DefenCath supply agreement with a Large Dialysis Operator.
- Anticipates FDA sNDA submission for REZZAYO in Q3 2026.
Price Impact
More from CRMD